Cardiac markers for non-invasive prediction of coronary reperfusion in myocardial infarction - Including data from the I.S.A.M. study;Enzymatische marker der reperfusion bei akutem myokardinfarkt - Mit daten aus der I.S.A.M.-studie

Herz

Volumn 24, Issue 6, 1999, Pages 430-439

  Walter, Sabine ^d   Carlsson, Joerg ^a   Schröder, Rolf ^b   Neuhaus, Karl Ludwig ^d   Sorges, Eckhardt ^d   Tebbe, Ulrich ^c  

^a KERCKHOFF HEART CENTER   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c KLINIKUM LIPPE DETMOLD   (Germany)

^d NONE

Author keywords

Cardiac markers; I.S.A.M study; Reperfusion; Thrombolysis

Indexed keywords

CREATINE KINASE; LACTATE DEHYDROGENASE; MYOGLOBIN; TROPONIN;

ACUTE HEART INFARCTION; ARTICLE; CORONARY ARTERY BLOOD FLOW; DATA ANALYSIS; DIAGNOSTIC VALUE; HEART INFARCTION SIZE; HUMAN; MAJOR CLINICAL STUDY;

EID: 0032884677     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03044429     Document Type: Article

References (45)

1. Abe S, Arima S, Yamashita T, et al. Early assessment of reperfusion therapy using cardiac troponin T. Am Coll Cardiol 1994; 23:1382-9.
2. Antmann EM, Braunwald E. Acute myocardial infarction. In: Braunwald E, ed. Heart disease. A textbook of cardiovascular medicine, 5th edn. Philadelphia: Saunders, 1997:1184.
3. Apple FS, Henry TD, Berger CR, et al. Early monitoring of serum cardiac troponin I for assessment of coronary reperfusion following thrombolytic therapy. Am J Clin Pathol 1996;105:6-10.
4. Danne O, Störk T, Möckel M, et al. Myoglobin beim akuten Myokardinfarkt. Reperfusionsdiagnoslik nach Thrombolyse. Intensivmedizin 1995;32:138-46.
5. Ellis AK, Little T, Masud AR, et al. Patterns of myoglobin release after reperfusion of injured myocardium. Circulation 1985; 72:639-47.
6. Fibrinolytic Therapy Trialists (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343:311.
7. Frey N, Müller Bardorff M, et al. Wertigkeit von Laborparametern bei der Risikostralifizierung von Patienten mit koronarer Herzkrankheit und chronischer Myokardischämie. Z Kardiol 1998;87:Suppl 2:100-5.
8. Granger CB, Califf RM, Topol EJ. Thrombolytic therapy for acute myocardial infarction: A review. Drugs 1992;44:293.
9. Gruppo Italiano Per Lo Studio della Streptochinase Nell' Infarct Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:397.
10. Gulba DC, Tanswell P, Dechend R, et al. Sixty-minute alteplase protocol: a new accelerated recombinant tissue-type plasminogen activator regimen for thrombolysis in acute myocardial infarction. J Am Coll Cardiol 1997;30:1611-7.
11. GUSTO-I Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular funktion and survival after acute myocardial infarction. N Engl J Med 1993;329:1615-22.
12. Hamm CW. Die Troponine - neue Marker zum Nachweis einer Myokardzellschädigung. Fortschr Med 1996;32:47-50.
13. Hamm CW, Goldmann BU, Heeschen C, et al. Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I. N Engl J Med 1997; 337:1648-53.
14. Hamm CW, Heeschen C, Goldmann B, et al. Benefit of Abciximab in patients with refractory unstable angina in relation to serum troponin T levels. N Engl J Med 1999;340:1623-9.
15. Hogg KH, Hornung RS, Howie CA, et al. Electrocardiographic prediction of coronary artery patency after thrombolytic treatment in acute myocardial infarction: Use of the ST segment as a noninvasive marker. Br Heart J 1988;60:275-80.
16. Hohnloser SH, Zabel M, Kasper W, et al. Assessment of coronary artery patency after thrombolytic therapy: accurate prediction utilizing the combined analysis of three noninvasive markers. J Am Coll Cardiol 1991;18:44-9.
17. Hornykewycz S, Gabriel H, Huber K. Biochemical markers of myocardial necrosis in acute myocardial infarction and thrombolysis. Ann Hematol 1994;69:Suppl II:59-63.
18. The I.S.A.M.-Study Group. A prospective trial of intravenous streptokinase in acute myocardial infarction. N Eng J Med 1986;314:1465-71.
19. Jurlander B, Clemmensen P, Magnus Ohman E, et al. Serum myoglobin for the early non-invasive detection of coronary reperfusion in patients with acute myocardial infarction. Eur Heart J 1996;17:399-406.
20. Kaiser H, Spaar U, Sold G, et al. Radioimmunologische Bestimmung von Human-Myoglobin in der Diagnostik des akuten Myokardinfarkts. Klin Wochenschr 1979;57:225-35.
21. Kircher BJ, Topol EJ, O'Neill WW, et al. Prediction of infarct coronary artery recanalization after intravenous thrombolytic therapy. Am J Cardiol 1987;59:513-5.
22. Krucoff MW, Green CE, Satler LF, et al. Noninvasive detection of coronary artery patency using continuous ST-segment monitoring. Am J Cardiol 1986;57:916-22.
23. Laperche T, Golmard JL, Steg G, for the PERM Study Group. Early behavior of biochemical markers in patients with Thrombolysis in Myocardial Infarction grade 2 flow in the infarct artery as opposed to other flow grades after intravenous thrombolysis for acute myocardial infarction. Am Heart J 1997;134:1044-51.
24. Lavin F, Kane M, Forde A, et al. Comparison of five cardiac markers in the detection of reperfusion after thrombolysis in acute myocardial infarction. Br Heart J 995;73:422-7.
25. Lewis BS, Ganz W, Laramee P, et al. Usefulness of a rapid initial increase in plasma creatine kinase activity as a marker of reperfusion during thrombolytic therapy for acute myocardial infarction. Am J Cardiol 1988;62:20-4.
26. Lindahl B, Venge P, Wallentin L, for the Fragmin in unstable coronary artery disease (FRISC) Study Group. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. J Am Coll Cardiol 1997;29:43-8.
27. Mair J, Puschendorf B. Neue Laborparameter zur Diagnose und Überwachung akuter Myokardschäden. DG Klinische Chemie -Mitteilungen 1994;25:1-16.
28. Meierhenrich R, Sorges E, Götz J, et al. Thrombolytische Therapie bei Herzinfarkt, Lungenembolie und Venenthrombose. Intensivmedizin 1997;34:58-68.
29. Neuhaus KL, Tebbe U, Sauer G, et al. High dose intravenous Streptokinase in acute myocardial infarction. Clin Cardiol 1983; 6:426-34.
30. Neuhaus KL, Tebbe U, Gottwik M, et al. Intravenous recombinant tissue plasminogen activator (rt-PA) and urokinase in acute myocardial infarction: Results of the German Activator Urokinase Study (GAUS). J Am Coll Cardiol 1988;12:581-7.
31. Neuhaus KL, Feuerer W, Jeep-Tebbe S, et al. Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. J Am Coll Cardiol 1989;14:1566-9.
32. Prellwitz DW. Die klinische Bedeutung der Konzentrationsbestimmung der Troponine. Dtsch Med Wochenschr 1994;119: 1013-5.
33. Schröder R, Biamino G, von Leitner ER, et al. Intravenous short-term infusion of streptokinase in acute myocardial infarction. Circulation 1983;67:536-548.
34. Stewart JT, French JK, Theroux P, et al. Early noninvasive identification of failed reperfusion after intravenous thrombolytic therapy in acute myocardial infarction. J Am Coll Cardiol 1998;31:1499-505.
35. Störk T, Möckel M, für die NOWIS Studiengruppe. Beitrag des Labors zur Diagnostik und Risikostratifikation bei akuten Koronarsyndromen in der klinischen Routine (NOWIS). Intensivmedizin 1998;35:42-9.
36. Thomas L, Hrsg. Labor und Diagnose, 4. Aufl. Marburg: Medizinische Verlagsgesellschaft, 1995.
37. Vogt A, von Essen R, Tebbe U, et al. Impact of early perfusion status of the infarct-related artery on short-term mortality after thrombolysis for acute myocardial infarction: Retrospective analysis of four German multicenter studies. J Am Coll Cardiol 1993;21:1391.
38. Voth E, Tebbe U, Schicha H, et al. and the I.S.A.M Study Group. Intravenous Streptokinase in Acute Myocardial Infarction (I.S.A.M.) Trial: Serial evaluation of left ventricular function up to 3 years after infarction estimated by radionuclide ventriculography. J Am Coll Cardiol 1991;18:1610-6.
39. Walter S, Carlsson J, Tebbe U. Troponin und Myoglobin - Stellenwert in der Diagnostik akuter koronarer Syndrome. Notfall & Rettungsmedizin 1999;2:263-6.
40. White HD, Aylward PE, Frey MJ et al. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog early reperfusion/occlusion (HERO) trial investigators. Circulation 1997;96:2155-61.
41. Winter RJ de, Koster RW, Sturk A, et al. Value of myoglobin, troponin T, and CK-MB mass in ruling out an acute myocardial infarction in the emergency room. Circulation 1995;92:3401-7.
42. Wong CK, French JK, Aylward PE, et al. Usefulness of the presenting electrocardiogram in predicting successful reperfusion with streptokinase in acute myocardial infarction. Am J Cardiol 1999;83:164-8.
43. Woodfield SL, Lundergan CF, Reiner JS, et al. Gender and acute myocardial infarction: is there a different response to thrombolysis? J Am Coll Cardiol 1997;29:35-42.
44. Zabel M, Hohnloser SH, Köster W, et al. Analysis of creatine kinase, CK-MB, myoglobin, and troponin T time-activity curves for early assessment of coronary artery reperfusion after intravenous thrombolysis. Circulation 1993;87:1542-50.
45. Zeymer U, Tebbe U, Essen RV, et al. Influence of time to treatment on early infarct-related artery patency after different thrombolytic regimens. ALKK-Study Group. Am Heart J 1999; 137:34-8.